Search - tctmd.com

Displaying 61 - 74 of 74

Sort: Relevancy | Date

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

Presentation TCT 2014

PCI and Anticoagulation: Triple Therapy

Presenter: Jurrien M. Ten Berg

September 13, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and Triple Therapy

Presenter: George D. Dangas

April 13, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

Presenter: George Dangas

April 12, 2014

Presentation TCT 2013

Outcomes of Patients Treated with Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (From the Harmonizing...

Presenter: Eugenia Nikolsky

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

Presenter: Eugenia Nikolsky

October 28, 2013

Presentation Scripps 2013

The Challenges of Triple Therapy: Managing the DES Patient Who Also Requires Anti-coagulation

Presenter: C. Michael Gibson

October 03, 2013

Presentation

Comparison of Dual vs. Triple Antiplatelet Therapy After DES According to Stent Length

Presenter: S-W Lee

September 26, 2013

Presentation

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Presenter: Y. Naruse

August 26, 2013

Presentation TVT 2013

Is Triple Therapy a Triple Threat for Patients? DAPT and Chronic Anticoagulation

Presenter: Ted Feldman

June 15, 2013

Presentation Fellows 2013

Navigating the New Chronic Oral Anticoagulants and How to Deal with Triple Therapy

Presenter: Manesh Patel

April 16, 2013

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Presentation

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Presenter: M. Lamberts

August 10, 2012

Advertisement

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

PCI and Anticoagulation: Triple Therapy

Navigating the New Oral Anticoagulants and Triple Therapy

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

Outcomes of Patients Treated with Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (From the Harmonizing...

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

The Challenges of Triple Therapy: Managing the DES Patient Who Also Requires Anti-coagulation

Comparison of Dual vs. Triple Antiplatelet Therapy After DES According to Stent Length

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Is Triple Therapy a Triple Threat for Patients? DAPT and Chronic Anticoagulation

Navigating the New Chronic Oral Anticoagulants and How to Deal with Triple Therapy

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content